Clinical Trials | A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
The University of Virginia seeks adult women ages 18 years and older with recurrent endometrial cancer or high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancer. This study aims to determine response to the treatment of IMGN151. You may be eligible for this study if: • You have a confirmed diagnosis of recurrent endometrial cancer or platinum-resistant, high-grade serous epithelial ovarian cancer (PROC), primary peritoneal or fallopian tube cancer. • Have had 1-4 prior lines of therapy for your cancer. This study involves blood sampling, archival tissue collection, physical examination, imaging of the chest, abdomen and pelvis, eye exams, an echocardiogram (ECHO), and an electrocardiogram (ECG). Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. https://clinicaltrials.gov/study/NCT05527184